Search BOLT
Bolt Biotherapeutics, Inc.
Nasdaq · CIK 1641281
Last close3.45
Daily change-0.06 (-1.71%)
10 Years gain-99.46%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BOLT · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
55.6Momentum
100.0Acceleration
60.0Confidence
91.0Annual Revenue6
Quarterly Revenue22
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.8 / 25
Quality16.4 / 25
Capital Efficiency2.4 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1049.7319 percentage points.
Share count reductionDiluted share count declined 11.8112%.
Warnings
ROIC declining · MEDIUMROIC declined by 1206.5052 percentage points.
Key Metrics
Revenue Growth TTM10.06%OK
Revenue CAGR 3Y10.33%OK
Gross Margin100%OK
Operating Margin-821.38%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-1,724.06%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-11.81%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $7.70M | $7.70M | -$36.11M | -$39.85M | -$39.92M | 100% | -469.3% | -518.8% | -642.91% | 1.87M |
| 2025 FY Dec 31, 2024 | $7.69M | $7.69M | -$73.05M | -$61.29M | -$61.33M | 100% | -949.91% | -797.53% | -565.02% | 1.91M |
| 2024 FY Dec 31, 2023 | $7.88M | $7.88M | -$76.20M | -$69.53M | -$69.73M | 100% | -967.45% | -885.36% | -914.12% | 37.81M |
| 2023 FY Dec 31, 2022 | $5.73M | $5.73M | -$90.32M | -$76.50M | -$78.46M | 100% | -1,576.56% | -1,369.47% | -214.54% | 37.36M |
| 2022 FY Dec 31, 2021 | $1.26M | $1.26M | -$92.79M | -$57.07M | -$59.40M | 100% | -7,364.13% | -4,714.6% | n/a | 33.2M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $4.00M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-344597, 0001193125-25-277549 |
| Revenue Growth TTM | 10.06% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-344597, 0001193125-25-277549 |
| Revenue CAGR 3Y | 10.33% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-104121 |
| Revenue CAGR 5Y | 101.61% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-104121 |
| Gross Profit CAGR 3Y | 10.33% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-104121 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-344597, 0001193125-25-277549 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-344597, 0001193125-25-277549 |
| Operating Margin | -821.38% | Operating Income / Revenue | OK | 0001193125-26-344597, 0001193125-25-277549 |
| ROIC | -1,724.06% | NOPAT / Average Invested Capital | OK | 0001193125-26-344597, 0001193125-25-277549 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-344597 |
| Current Ratio | 2.61x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.37 | Revenue / Diluted Shares | OK | 0001193125-26-344597, 0001193125-25-277549 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |